IOVANCE BIOTHERAPEUTICS, INC. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2012 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Iovance Biotherapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2012 to Q4 2023.
  • Iovance Biotherapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $447M, a 27.5% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $447M +$96.4M +27.5% Dec 31, 2023 10-K 2024-02-28
Q4 2022 $350M +$82.9M +31% Dec 31, 2022 10-K 2024-02-28
Q4 2021 $267M +$78.1M +41.2% Dec 31, 2021 10-K 2023-02-28
Q4 2020 $189M +$60.7M +47.2% Dec 31, 2020 10-K 2022-02-24
Q4 2019 $129M +$50.6M +64.7% Dec 31, 2019 10-K 2021-02-25
Q4 2018 $78.1M +$30.3M +63.3% Dec 31, 2018 10-K 2020-02-25
Q4 2017 $47.8M +$6.45M +15.6% Dec 31, 2017 10-K 2019-02-28
Q4 2016 $41.4M +$22.1M +114% Dec 31, 2016 10-K 2018-03-12
Q4 2015 $19.3M +$10.9M +130% Dec 31, 2015 10-K 2017-03-09
Q4 2014 $8.43M +$4.75M +129% Dec 31, 2014 10-K 2016-03-11
Q4 2013 $3.68M +$10.6M Dec 31, 2013 10-K 2015-03-16
Q4 2012 -$6.96M Dec 31, 2012 10-K 2014-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.